

Non-Insulin Therapies for Diabetes-EMEA Market Status and Trend Report 2013-2023

<https://marketpublishers.com/r/NAD4E589FF6MEN.html>

Date: May 2018

Pages: 154

Price: US\$ 3,480.00 (Single User License)

ID: NAD4E589FF6MEN

Abstracts

Report Summary

Non-Insulin Therapies for Diabetes-EMEA Market Status and Trend Report 2013-2023 offers a comprehensive analysis on Non-Insulin Therapies for Diabetes industry, standing on the readers' perspective, delivering detailed market data and penetrating insights. No matter the client is industry insider, potential entrant or investor, the report will provide useful data and information. Key questions answered by this report include:

Whole EMEA and Regional Market Size of Non-Insulin Therapies for Diabetes 2013-2017, and development forecast 2018-2023

Main market players of Non-Insulin Therapies for Diabetes in EMEA, with company and product introduction, position in the Non-Insulin Therapies for Diabetes market
Market status and development trend of Non-Insulin Therapies for Diabetes by types and applications

Cost and profit status of Non-Insulin Therapies for Diabetes, and marketing status

Market growth drivers and challenges

The report segments the EMEA Non-Insulin Therapies for Diabetes market as:

EMEA Non-Insulin Therapies for Diabetes Market: Regional Segment Analysis (Regional Consumption Volume, Consumption Volume, Revenue and Growth Rate 2013-2023):

Europe

Middle East

Africa

EMEA Non-Insulin Therapies for Diabetes Market: Product Type Segment Analysis
(Consumption Volume, Average Price, Revenue, Market Share and Trend 2013-2023):

- Alpha-glucosidase Inhibitors
- Amylin Agonists
- Biguanides
- Dipeptidyl Peptidase-4 (DPP4) Inhibitors
- Glinides / Meglitinides
- GLP-1 Analogs / GLP-1 Agonists
- Sodium-glucose Cotransporter 2 (SGLT2) Inhibitors
- Sulfonylureas
- Thiazolidinediones
- Others

EMEA Non-Insulin Therapies for Diabetes Market: Application Segment Analysis
(Consumption Volume and Market Share 2013-2023; Downstream Customers and Market Analysis)

- Hospital Pharmacy
- Retail Pharmacies
- Online Pharmacy
- Others

EMEA Non-Insulin Therapies for Diabetes Market: Players Segment Analysis (Company and Product introduction, Non-Insulin Therapies for Diabetes Sales Volume, Revenue, Price and Gross Margin):

- GSK
- Eli Lilly
- Sumitomo Dainippon Pharma
- Intarcia Therapeutics
- Servier
- Jiangsu Hansoh Pharmaceutical
- Novo Nordisk
- Emisphere
- Uni-Bio Science Group
- Takeda

3SBio
Merck
Dong-A Pharmaceutical
Luye Pharma Group
Eurofarma
Geropharm
Alkem Labs
SatRx
Pfizer
Jiangsu Hengrui Medicine

In a word, the report provides detailed statistics and analysis on the state of the industry; and is a valuable source of guidance and direction for companies and individuals interested in the market.

Contents

CHAPTER 1 OVERVIEW OF NON-INSULIN THERAPIES FOR DIABETES

- 1.1 Definition of Non-Insulin Therapies for Diabetes in This Report
- 1.2 Commercial Types of Non-Insulin Therapies for Diabetes
 - 1.2.1 Alpha-glucosidase Inhibitors
 - 1.2.2 Amylin Agonists
 - 1.2.3 Biguanides
 - 1.2.4 Dipeptidyl Peptidase-4 (DPP4) Inhibitors
 - 1.2.5 Glinides / Meglitinides
 - 1.2.6 GLP-1 Analogs / GLP-1 Agonists
 - 1.2.7 Sodium-glucose Cotransporter 2 (SGLT2) Inhibitors
 - 1.2.8 Sulfonylureas
 - 1.2.9 Thiazolidinediones
 - 1.2.10 Others
- 1.3 Downstream Application of Non-Insulin Therapies for Diabetes
 - 1.3.1 Hospital Pharmacy
 - 1.3.2 Retail Pharmacies
 - 1.3.3 Online Pharmacy
 - 1.3.4 Others
- 1.4 Development History of Non-Insulin Therapies for Diabetes
- 1.5 Market Status and Trend of Non-Insulin Therapies for Diabetes 2013-2023
 - 1.5.1 Asia Pacific Non-Insulin Therapies for Diabetes Market Status and Trend 2013-2023
 - 1.5.2 Regional Non-Insulin Therapies for Diabetes Market Status and Trend 2013-2023

CHAPTER 2 ASIA PACIFIC MARKET STATUS AND FORECAST BY REGIONS

- 2.1 Market Status of Non-Insulin Therapies for Diabetes in Asia Pacific 2013-2017
- 2.2 Consumption Market of Non-Insulin Therapies for Diabetes in Asia Pacific by Regions
 - 2.2.1 Consumption Volume of Non-Insulin Therapies for Diabetes in Asia Pacific by Regions
 - 2.2.2 Revenue of Non-Insulin Therapies for Diabetes in Asia Pacific by Regions
- 2.3 Market Analysis of Non-Insulin Therapies for Diabetes in Asia Pacific by Regions
 - 2.3.1 Market Analysis of Non-Insulin Therapies for Diabetes in China 2013-2017
 - 2.3.2 Market Analysis of Non-Insulin Therapies for Diabetes in Japan 2013-2017

- 2.3.3 Market Analysis of Non-Insulin Therapies for Diabetes in Korea 2013-2017
- 2.3.4 Market Analysis of Non-Insulin Therapies for Diabetes in India 2013-2017
- 2.3.5 Market Analysis of Non-Insulin Therapies for Diabetes in Southeast Asia 2013-2017
- 2.3.6 Market Analysis of Non-Insulin Therapies for Diabetes in Australia 2013-2017
- 2.4 Market Development Forecast of Non-Insulin Therapies for Diabetes in Asia Pacific 2018-2023
 - 2.4.1 Market Development Forecast of Non-Insulin Therapies for Diabetes in Asia Pacific 2018-2023
 - 2.4.2 Market Development Forecast of Non-Insulin Therapies for Diabetes by Regions 2018-2023

CHAPTER 3 ASIA PACIFIC MARKET STATUS AND FORECAST BY TYPES

- 3.1 Whole Asia Pacific Market Status by Types
 - 3.1.1 Consumption Volume of Non-Insulin Therapies for Diabetes in Asia Pacific by Types
 - 3.1.2 Revenue of Non-Insulin Therapies for Diabetes in Asia Pacific by Types
- 3.2 Asia Pacific Market Status by Types in Major Countries
 - 3.2.1 Market Status by Types in China
 - 3.2.2 Market Status by Types in Japan
 - 3.2.3 Market Status by Types in Korea
 - 3.2.4 Market Status by Types in India
 - 3.2.5 Market Status by Types in Southeast Asia
 - 3.2.6 Market Status by Types in Australia
- 3.3 Market Forecast of Non-Insulin Therapies for Diabetes in Asia Pacific by Types

CHAPTER 4 ASIA PACIFIC MARKET STATUS AND FORECAST BY DOWNSTREAM INDUSTRY

- 4.1 Demand Volume of Non-Insulin Therapies for Diabetes in Asia Pacific by Downstream Industry
- 4.2 Demand Volume of Non-Insulin Therapies for Diabetes by Downstream Industry in Major Countries
 - 4.2.1 Demand Volume of Non-Insulin Therapies for Diabetes by Downstream Industry in China
 - 4.2.2 Demand Volume of Non-Insulin Therapies for Diabetes by Downstream Industry in Japan
 - 4.2.3 Demand Volume of Non-Insulin Therapies for Diabetes by Downstream Industry

in Korea

4.2.4 Demand Volume of Non-Insulin Therapies for Diabetes by Downstream Industry in India

4.2.5 Demand Volume of Non-Insulin Therapies for Diabetes by Downstream Industry in Southeast Asia

4.2.6 Demand Volume of Non-Insulin Therapies for Diabetes by Downstream Industry in Australia

4.3 Market Forecast of Non-Insulin Therapies for Diabetes in Asia Pacific by Downstream Industry

CHAPTER 5 MARKET DRIVING FACTOR ANALYSIS OF NON-INSULIN THERAPIES FOR DIABETES

5.1 Asia Pacific Economy Situation and Trend Overview

5.2 Non-Insulin Therapies for Diabetes Downstream Industry Situation and Trend Overview

CHAPTER 6 NON-INSULIN THERAPIES FOR DIABETES MARKET COMPETITION STATUS BY MAJOR PLAYERS IN ASIA PACIFIC

6.1 Sales Volume of Non-Insulin Therapies for Diabetes in Asia Pacific by Major Players

6.2 Revenue of Non-Insulin Therapies for Diabetes in Asia Pacific by Major Players

6.3 Basic Information of Non-Insulin Therapies for Diabetes by Major Players

6.3.1 Headquarters Location and Established Time of Non-Insulin Therapies for Diabetes Major Players

6.3.2 Employees and Revenue Level of Non-Insulin Therapies for Diabetes Major Players

6.4 Market Competition News and Trend

6.4.1 Merger, Consolidation or Acquisition News

6.4.2 Investment or Disinvestment News

6.4.3 New Product Development and Launch

CHAPTER 7 NON-INSULIN THERAPIES FOR DIABETES MAJOR MANUFACTURERS INTRODUCTION AND MARKET DATA

7.1 GSK

7.1.1 Company profile

7.1.2 Representative Non-Insulin Therapies for Diabetes Product

7.1.3 Non-Insulin Therapies for Diabetes Sales, Revenue, Price and Gross Margin of

GSK

7.2 Eli Lilly

7.2.1 Company profile

7.2.2 Representative Non-Insulin Therapies for Diabetes Product

7.2.3 Non-Insulin Therapies for Diabetes Sales, Revenue, Price and Gross Margin of Eli Lilly

7.3 Sumitomo Dainippon Pharma

7.3.1 Company profile

7.3.2 Representative Non-Insulin Therapies for Diabetes Product

7.3.3 Non-Insulin Therapies for Diabetes Sales, Revenue, Price and Gross Margin of Sumitomo Dainippon Pharma

7.4 Intarcia Therapeutics

7.4.1 Company profile

7.4.2 Representative Non-Insulin Therapies for Diabetes Product

7.4.3 Non-Insulin Therapies for Diabetes Sales, Revenue, Price and Gross Margin of Intarcia Therapeutics

7.5 Servier

7.5.1 Company profile

7.5.2 Representative Non-Insulin Therapies for Diabetes Product

7.5.3 Non-Insulin Therapies for Diabetes Sales, Revenue, Price and Gross Margin of Servier

7.6 Jiangsu Hansoh Pharmaceutical

7.6.1 Company profile

7.6.2 Representative Non-Insulin Therapies for Diabetes Product

7.6.3 Non-Insulin Therapies for Diabetes Sales, Revenue, Price and Gross Margin of Jiangsu Hansoh Pharmaceutical

7.7 Novo Nordisk

7.7.1 Company profile

7.7.2 Representative Non-Insulin Therapies for Diabetes Product

7.7.3 Non-Insulin Therapies for Diabetes Sales, Revenue, Price and Gross Margin of Novo Nordisk

7.8 Emisphere

7.8.1 Company profile

7.8.2 Representative Non-Insulin Therapies for Diabetes Product

7.8.3 Non-Insulin Therapies for Diabetes Sales, Revenue, Price and Gross Margin of Emisphere

7.9 Uni-Bio Science Group

7.9.1 Company profile

7.9.2 Representative Non-Insulin Therapies for Diabetes Product

- 7.9.3 Non-Insulin Therapies for Diabetes Sales, Revenue, Price and Gross Margin of Uni-Bio Science Group
- 7.10 Takeda
 - 7.10.1 Company profile
 - 7.10.2 Representative Non-Insulin Therapies for Diabetes Product
 - 7.10.3 Non-Insulin Therapies for Diabetes Sales, Revenue, Price and Gross Margin of Takeda
- 7.11 3SBio
 - 7.11.1 Company profile
 - 7.11.2 Representative Non-Insulin Therapies for Diabetes Product
 - 7.11.3 Non-Insulin Therapies for Diabetes Sales, Revenue, Price and Gross Margin of 3SBio
- 7.12 Merck
 - 7.12.1 Company profile
 - 7.12.2 Representative Non-Insulin Therapies for Diabetes Product
 - 7.12.3 Non-Insulin Therapies for Diabetes Sales, Revenue, Price and Gross Margin of Merck
- 7.13 Dong-A Pharmaceutical
 - 7.13.1 Company profile
 - 7.13.2 Representative Non-Insulin Therapies for Diabetes Product
 - 7.13.3 Non-Insulin Therapies for Diabetes Sales, Revenue, Price and Gross Margin of Dong-A Pharmaceutical
- 7.14 Luye Pharma Group
 - 7.14.1 Company profile
 - 7.14.2 Representative Non-Insulin Therapies for Diabetes Product
 - 7.14.3 Non-Insulin Therapies for Diabetes Sales, Revenue, Price and Gross Margin of Luye Pharma Group
- 7.15 Eurofarma
 - 7.15.1 Company profile
 - 7.15.2 Representative Non-Insulin Therapies for Diabetes Product
 - 7.15.3 Non-Insulin Therapies for Diabetes Sales, Revenue, Price and Gross Margin of Eurofarma
- 7.16 Geropharm
- 7.17 Alkem Labs
- 7.18 SatRx
- 7.19 Pfizer
- 7.20 Jiangsu Hengrui Medicine

CHAPTER 8 UPSTREAM AND DOWNSTREAM MARKET ANALYSIS OF NON-

INSULIN THERAPIES FOR DIABETES

- 8.1 Industry Chain of Non-Insulin Therapies for Diabetes
- 8.2 Upstream Market and Representative Companies Analysis
- 8.3 Downstream Market and Representative Companies Analysis

CHAPTER 9 COST AND GROSS MARGIN ANALYSIS OF NON-INSULIN THERAPIES FOR DIABETES

- 9.1 Cost Structure Analysis of Non-Insulin Therapies for Diabetes
- 9.2 Raw Materials Cost Analysis of Non-Insulin Therapies for Diabetes
- 9.3 Labor Cost Analysis of Non-Insulin Therapies for Diabetes
- 9.4 Manufacturing Expenses Analysis of Non-Insulin Therapies for Diabetes

CHAPTER 10 MARKETING STATUS ANALYSIS OF NON-INSULIN THERAPIES FOR DIABETES

- 10.1 Marketing Channel
 - 10.1.1 Direct Marketing
 - 10.1.2 Indirect Marketing
 - 10.1.3 Marketing Channel Development Trend
- 10.2 Market Positioning
 - 10.2.1 Pricing Strategy
 - 10.2.2 Brand Strategy
 - 10.2.3 Target Client
- 10.3 Distributors/Traders List

CHAPTER 11 REPORT CONCLUSION

CHAPTER 12 RESEARCH METHODOLOGY AND REFERENCE

- 12.1 Methodology/Research Approach
 - 12.1.1 Research Programs/Design
 - 12.1.2 Market Size Estimation
 - 12.1.3 Market Breakdown and Data Triangulation
- 12.2 Data Source
 - 12.2.1 Secondary Sources
 - 12.2.2 Primary Sources
- 12.3 Reference

I would like to order

Product name: Non-Insulin Therapies for Diabetes-EMEA Market Status and Trend Report 2013-2023

Product link: <https://marketpublishers.com/r/NAD4E589FF6MEN.html>

Price: US\$ 3,480.00 (Single User License / Electronic Delivery)

If you want to order Corporate License or Hard Copy, please, contact our Customer Service:

info@marketpublishers.com

Payment

To pay by Credit Card (Visa, MasterCard, American Express, PayPal), please, click button on product page <https://marketpublishers.com/r/NAD4E589FF6MEN.html>

To pay by Wire Transfer, please, fill in your contact details in the form below:

First name:
Last name:
Email:
Company:
Address:
City:
Zip code:
Country:
Tel:
Fax:
Your message:

****All fields are required**

Customer signature _____

Please, note that by ordering from marketpublishers.com you are agreeing to our Terms & Conditions at <https://marketpublishers.com/docs/terms.html>

To place an order via fax simply print this form, fill in the information below and fax the completed form to +44 20 7900 3970